These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
606 related articles for article (PubMed ID: 15913839)
21. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011 [TBL] [Abstract][Full Text] [Related]
22. Active glycogen synthase kinase-3 and tau pathology-related tyrosine phosphorylation in pR5 human tau transgenic mice. Köhler C; Dinekov M; Götz J Neurobiol Aging; 2013 May; 34(5):1369-79. PubMed ID: 23294633 [TBL] [Abstract][Full Text] [Related]
23. Interneuronal transfer of human tau between Lamprey central neurons in situ. Kim W; Lee S; Jung C; Ahmed A; Lee G; Hall GF J Alzheimers Dis; 2010; 19(2):647-64. PubMed ID: 20110609 [TBL] [Abstract][Full Text] [Related]
24. The GABAergic septohippocampal connection is impaired in a mouse model of tauopathy. Soler H; Dorca-Arévalo J; González M; Rubio SE; Ávila J; Soriano E; Pascual M Neurobiol Aging; 2017 Jan; 49():40-51. PubMed ID: 27743524 [TBL] [Abstract][Full Text] [Related]
25. Ultrastructural neuronal pathology in transgenic mice expressing mutant (P301L) human tau. Lin WL; Lewis J; Yen SH; Hutton M; Dickson DW J Neurocytol; 2003 Nov; 32(9):1091-105. PubMed ID: 15044841 [TBL] [Abstract][Full Text] [Related]
26. Astrocytic neuroprotection through induction of cytoprotective molecules; a proteomic analysis of mutant P301S tau-transgenic mouse. Yata K; Oikawa S; Sasaki R; Shindo A; Yang R; Murata M; Kanamaru K; Tomimoto H Brain Res; 2011 Sep; 1410():12-23. PubMed ID: 21803337 [TBL] [Abstract][Full Text] [Related]
27. The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy. Hansen HH; Barkholt P; Fabricius K; Jelsing J; Terwel D; Pyke C; Knudsen LB; Vrang N Brain Res; 2016 Mar; 1634():158-170. PubMed ID: 26746341 [TBL] [Abstract][Full Text] [Related]
28. The twenty-four KDa C-terminal tau fragment increases with aging in tauopathy mice: implications of prion-like properties. Matsumoto SE; Motoi Y; Ishiguro K; Tabira T; Kametani F; Hasegawa M; Hattori N Hum Mol Genet; 2015 Nov; 24(22):6403-16. PubMed ID: 26374846 [TBL] [Abstract][Full Text] [Related]
29. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. Andorfer C; Kress Y; Espinoza M; de Silva R; Tucker KL; Barde YA; Duff K; Davies P J Neurochem; 2003 Aug; 86(3):582-90. PubMed ID: 12859672 [TBL] [Abstract][Full Text] [Related]
30. Phosphorylation and oligomerization of α-synuclein associated with GSK-3β activation in the rTg4510 mouse model of tauopathy. Takaichi Y; Chambers JK; Inoue H; Ano Y; Takashima A; Nakayama H; Uchida K Acta Neuropathol Commun; 2020 Jun; 8(1):86. PubMed ID: 32560668 [TBL] [Abstract][Full Text] [Related]
31. Tauopathies and tau oligomers. Takashima A J Alzheimers Dis; 2013; 37(3):565-8. PubMed ID: 23948895 [TBL] [Abstract][Full Text] [Related]
32. Drosophila models of human tauopathies indicate that Tau protein toxicity in vivo is mediated by soluble cytosolic phosphorylated forms of the protein. Feuillette S; Miguel L; Frébourg T; Campion D; Lecourtois M J Neurochem; 2010 May; 113(4):895-903. PubMed ID: 20193038 [TBL] [Abstract][Full Text] [Related]
33. Deletion of murine tau gene increases tau aggregation in a human mutant tau transgenic mouse model. Ando K; Leroy K; Heraud C; Kabova A; Yilmaz Z; Authelet M; Suain V; De Decker R; Brion JP Biochem Soc Trans; 2010 Aug; 38(4):1001-5. PubMed ID: 20658993 [TBL] [Abstract][Full Text] [Related]
34. Unique pathological tau conformers from Alzheimer's brains transmit tau pathology in nontransgenic mice. Guo JL; Narasimhan S; Changolkar L; He Z; Stieber A; Zhang B; Gathagan RJ; Iba M; McBride JD; Trojanowski JQ; Lee VM J Exp Med; 2016 Nov; 213(12):2635-2654. PubMed ID: 27810929 [TBL] [Abstract][Full Text] [Related]
35. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Ishihara T; Hong M; Zhang B; Nakagawa Y; Lee MK; Trojanowski JQ; Lee VM Neuron; 1999 Nov; 24(3):751-62. PubMed ID: 10595524 [TBL] [Abstract][Full Text] [Related]
36. Distribution of spleen tyrosine kinase and tau phosphorylated at tyrosine 18 in a mouse model of tauopathy and in the human hippocampus. Köhler C; Fuhr V; Dinekov M Brain Res; 2017 Dec; 1677():1-13. PubMed ID: 28919467 [TBL] [Abstract][Full Text] [Related]
37. GSPE interferes with tau aggregation in vivo: implication for treating tauopathy. Santa-Maria I; Diaz-Ruiz C; Ksiezak-Reding H; Chen A; Ho L; Wang J; Pasinetti GM Neurobiol Aging; 2012 Sep; 33(9):2072-81. PubMed ID: 22054871 [TBL] [Abstract][Full Text] [Related]
38. Pinning down phosphorylated tau and tauopathies. Lim J; Lu KP Biochim Biophys Acta; 2005 Jan; 1739(2-3):311-22. PubMed ID: 15615648 [TBL] [Abstract][Full Text] [Related]
39. Tau Fibril Formation in Cultured Cells Compatible with a Mouse Model of Tauopathy. Matsumoto G; Matsumoto K; Kimura T; Suhara T; Higuchi M; Sahara N; Mori N Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772786 [TBL] [Abstract][Full Text] [Related]
40. Amphiphysin-1 protein level changes associated with tau-mediated neurodegeneration. De Jesús-Cortés HJ; Nogueras-Ortiz CJ; Gearing M; Arnold SE; Vega IE Neuroreport; 2012 Nov; 23(16):942-6. PubMed ID: 22975846 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]